Detalles de la búsqueda
1.
A phase I, randomized, double-blind, placebo-controlled, ascending single- and multiple-dose study of the pharmacokinetics, safety, and tolerability of oral ceftibuten in healthy adult subjects.
Antimicrob Agents Chemother
; 68(1): e0109923, 2024 Jan 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-38059635
2.
A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Biapenem in Healthy Adult Subjects.
Antimicrob Agents Chemother
; 65(5)2023 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33685898
3.
In vitro potency of xeruborbactam in combination with multiple ß-lactam antibiotics in comparison with other ß-lactam/ß-lactamase inhibitor (BLI) combinations against carbapenem-resistant and extended-spectrum ß-lactamase-producing Enterobacterales.
Antimicrob Agents Chemother
; 67(11): e0044023, 2023 11 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37800963
4.
In Vitro Activity of the Ultrabroad-Spectrum Beta-Lactamase Inhibitor QPX7728 in Combination with Multiple Beta-Lactam Antibiotics against Pseudomonas aeruginosa.
Antimicrob Agents Chemother
; 65(6)2021 05 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-33782010
5.
Single Intravenous Dose of Oritavancin for Treatment of Acute Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: Summary of Safety Analysis from the Phase 3 SOLO Studies.
Antimicrob Agents Chemother
; 62(4)2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29358292
6.
Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Vaborbactam and Meropenem Alone and in Combination following Single and Multiple Doses in Healthy Adult Subjects.
Antimicrob Agents Chemother
; 62(4)2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29437614
7.
Single-Dose Pharmacokinetics and Safety of Meropenem-Vaborbactam in Subjects with Chronic Renal Impairment.
Antimicrob Agents Chemother
; 62(3)2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-29311069
8.
Ex Vivo Characterization of Effects of Renal Replacement Therapy Modalities and Settings on Pharmacokinetics of Meropenem and Vaborbactam.
Antimicrob Agents Chemother
; 62(10)2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-30082292
9.
Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial.
JAMA
; 319(8): 788-799, 2018 02 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-29486041
10.
Effects of Oritavancin on Coagulation Tests in the Clinical Laboratory.
Antimicrob Agents Chemother
; 61(2)2017 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-27956417
11.
Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of the ß-Lactamase Inhibitor Vaborbactam (RPX7009) in Healthy Adult Subjects.
Antimicrob Agents Chemother
; 60(10): 6326-32, 2016 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-27527080
12.
Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa.
Am J Respir Crit Care Med
; 183(11): 1510-6, 2011 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-21471106
13.
Pharmacokinetics and safety of MP-376 (levofloxacin inhalation solution) in cystic fibrosis subjects.
Antimicrob Agents Chemother
; 55(6): 2636-40, 2011 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-21444699
14.
QPX7728, An Ultra-Broad-Spectrum B-Lactamase Inhibitor for Intravenous and Oral Therapy: Overview of Biochemical and Microbiological Characteristics.
Front Microbiol
; 12: 697180, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34290688
15.
Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial.
Infect Dis Ther
; 7(4): 439-455, 2018 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-30270406
16.
Carbapenem-Resistant Enterobacteriaceae Infections: Results From a Retrospective Series and Implications for the Design of Prospective Clinical Trials.
Open Forum Infect Dis
; 4(2): ofx063, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28584849
17.
Safety and efficacy of prolonged levofloxacin inhalation solution (APT-1026) treatment for cystic fibrosis and chronic Pseudomonas aeruginosa airway infection.
J Cyst Fibros
; 15(5): 634-40, 2016 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-26935334
18.
A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients.
J Cyst Fibros
; 15(4): 495-502, 2016 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-26852040
19.
A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients.
J Cyst Fibros
; 14(4): 507-14, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-25592656
20.
Pharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects.
Diagn Microbiol Infect Dis
; 50(2): 95-102, 2004 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-15474317
Resultados
1 -
20
de 20
1
Próxima >
>>